Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants. - Wikidata - awgldk - TriplyDB

Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants.

Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants.

http://www.wikidata.org/entity/Q34106732

about

The role of combined SNV and CNV burden in patients with distal symmetric polyneuropathy.Rescue of photoreceptor degeneration by curcumin in transgenic rats with P23H rhodopsin mutation.Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease.Polarization and myelination in myelinating glia.Depletion of molecular chaperones from the endoplasmic reticulum and fragmentation of the Golgi apparatus associated with pathogenesis in Pelizaeus-Merzbacher disease.Neuroprotective effects of curcumin.Molecular mechanisms of inherited demyelinating neuropathies.Effects of Fam83h overexpression on enamel and dentine formation.Curcumin facilitates a transitory cellular stress response in Trembler-J mice.The CMT4B disease-causing proteins MTMR2 and MTMR13/SBF2 regulate AKT signalling Experimental therapeutics in hereditary neuropathies: the past, the present, and the future.Curcumin and cancer cells: how many ways can curry kill tumor cells selectively?Cellular Pathology of Pelizaeus-Merzbacher Disease Involving Chaperones Associated with Endoplasmic Reticulum Stress Demyelinating prenatal and infantile developmental neuropathies.Murine therapeutic models for Charcot-Marie-Tooth (CMT) disease.Curcumin, a potential therapeutic candidate for retinal diseases.Animal models and therapeutic prospects for Charcot-Marie-Tooth disease.Naturally occurring plant polyphenols as potential therapies for inherited neuromuscular diseases.One gene, many neuropsychiatric disorders: lessons from Mendelian diseases.Endoplasmic reticulum quality control and dysmyelination.Promoting peripheral myelin repair.Endoplasmic Reticulum Protein Quality Control Failure in Myelin Disorders.Unfolded protein response, treatment and CMT1B.Therapeutic strategies for the inherited neuropathies.MpzR98C arrests Schwann cell development in a mouse model of early-onset Charcot-Marie-Tooth disease type 1B.The Charcot-Marie-Tooth diseases: how can we identify and develop novel therapeutic targets?Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice.Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B.Exome sequencing is an efficient tool for genetic screening of Charcot-Marie-Tooth disease.Congenital hypomyelinating neuropathy due to a novel MPZ mutation

P2860

Q30379223-4AB0C1A8-97EA-46A8-AD08-140A4799F127 Q33954730-EEBB376B-45A2-4782-AA8A-867DC3770B82 Q35946355-319AE580-7ABE-4149-B2E4-5A36F1E2E561 Q36498954-F61100DD-5AD9-46EF-B33C-C14412CE9268 Q36530065-2C0F7484-B3DD-4A22-9726-4A6F43DD975E Q36685119-6B1984FB-110E-45CC-9D90-37DF82B30AD9 Q36849490-2159BBB7-8637-4FC8-B9D7-6DBF2FF593FA Q36942808-6C3E0732-345D-417C-8CB7-5B65A5C11270 Q37060611-E5B55601-CFB3-4A1A-B077-4A21B353FE3D Q37286986-DD40FBA3-4FBB-471F-B3D5-E4EB7DA8B027 Q37294507-4CA8D4E8-E1AA-4A5A-A1AA-721CE3AE14A2 Q37329508-BA3CA7F9-C9E9-4682-A77B-7ECA978EE9FF Q37378063-B9F32E49-3DBB-47F1-BFBA-A38CC8D2D356 Q37662537-4E1099FD-31DA-460E-BB2C-AEF6833917D5 Q37998518-3CE3AEDA-1B44-4FC4-BA70-D711BFA6B826 Q38007033-BC083216-02D5-4BE2-A78D-7278278B6AE6 Q38082487-A33F37D4-1D71-4AAB-BF15-A116913571F8 Q38126454-243F9B9B-F9E1-4C21-8900-273E52BB4915 Q38161550-B59C0F84-93FD-41C4-9183-A6BC71F4FF12 Q38215322-E44BDB1F-530C-409F-A90D-FFACACF712D9 Q38472569-1ED71C07-D98F-4F4A-A5AF-02157FDC36DF Q38808666-504C86D7-53ED-4557-8E20-E35FC4446034 Q39094240-A0B9004F-0684-4265-AD91-9D211E445FF8 Q39496089-03CE01ED-4E55-47A6-AD0F-7F6AEA89D97E Q40316169-BF729840-BD7A-4EFF-A9E8-6D7589799975 Q42212358-C9FEC814-8A1A-4653-AA5C-98AA78F4C386 Q42416075-B6C556E3-5808-42D1-B8E4-8BFBA4B0FAB8 Q43244008-A3FB7C48-E31F-4D5F-B150-FD1455D3B388 Q52717186-0384B5C4-7CC5-41A3-BC62-A635EFF9B089 Q53370571-9EC02EFC-D1DD-4A6F-97CA-1CCF28C76473 Q58184270-FCD8F2F1-46F9-4B91-A812-CDB279D0C589

P2860

Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants.

http://www.wikidata.org/entity/Q34106732

description

2005 nî lūn-bûn

@nan

2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Curcumin treatment abrogates e ...... otein zero-truncating mutants.

@ast

Curcumin treatment abrogates e ...... otein zero-truncating mutants.

@en

Curcumin treatment abrogates e ...... otein zero-truncating mutants.

@nl

type

label

Curcumin treatment abrogates e ...... otein zero-truncating mutants.

@ast

Curcumin treatment abrogates e ...... otein zero-truncating mutants.

@en

Curcumin treatment abrogates e ...... otein zero-truncating mutants.

@nl

prefLabel

Curcumin treatment abrogates e ...... otein zero-truncating mutants.

@ast

Curcumin treatment abrogates e ...... otein zero-truncating mutants.

@en

Curcumin treatment abrogates e ...... otein zero-truncating mutants.

@nl

P1433

Q34106732-25650BAF-EF45-48C3-88B8-C2FD823EE9C3

P1476

Q34106732-4CFC2749-5FE1-4F9E-9221-7916D47154A1

P2093

Q34106732-0B6A7B77-FB95-4569-AA2E-7DF441DC5533

Q34106732-4ECD9A86-A0DA-48AC-911A-7C1947B70E66

Q34106732-A4CB1668-374E-4A82-8E33-0A3C64B96CF3

Q34106732-B360AC2F-F3EE-45EB-8349-479ABED04816

Q34106732-D5553558-7FAB-4CA3-BB18-8DF50C567F8D

P2860

Q34106732-0BC32CF2-B923-4C06-9D7C-B69AA037C027

Q34106732-0CCE1621-A3B0-4250-BEAF-844BCAF466F2

Q34106732-1A27B794-8FA8-448C-9C07-45BF0549CE66

Q34106732-503C10D9-A74F-40C4-8AD2-F5C4BFAD5214

Q34106732-5220A491-CBA4-40F3-ACB4-B69FE7BA1DBE

Q34106732-59DB7045-30C6-49D3-9CBC-E84DEE3DE09B

Q34106732-5FE5DB10-1BAF-4499-97E9-0D8D4376E87B

Q34106732-62B0F523-1F62-4E83-9C18-0EEF1D629B93

Q34106732-6FCAD6D1-11C8-4F49-8D25-FBEA803F2A2A

Q34106732-7008D321-8935-481E-BC57-DDD82BBC28A7

P304

Q34106732-11735064-778E-4470-A492-BCBAA76876C7

P31

Q34106732-EA4AA9FC-C9CC-47FC-B718-62412C282948

P356

Q34106732-DABFD739-8895-495F-A0E5-B2B77ADCF11E

P407

Q34106732-01C09D7B-E5EF-4FEF-B9E3-8C81E3CEF27E

P433

Q34106732-52F462E5-BCEE-40E3-85AB-B2BDF7DDE9B7

P478

Q34106732-6BEC00A6-6F8A-49DE-817A-AA2FC3AC6437

P50

Q34106732-B6DB8F6A-3157-476C-B514-F1D25BC3D05A

P577

Q34106732-12B4EF83-F311-4C0C-A132-2BA4719568FD

P5875

Q34106732-4C310D9C-4B3C-4EEF-9DFA-6599DBD629C8

P698

Q34106732-F556CA55-C839-4194-95F8-465534233C5F

P921

Q34106732-7bd25f4d-93c5-430e-a31d-1decfe3f9653

Q34106732-E8A76D22-0A4D-420E-BEAF-2F73488A6EE9

P932

Q34106732-A06FA617-5025-4368-A2CE-7DDD8C15C78D

P356

P1433

American Journal of Human Genetics

P1476

Curcumin treatment abrogates e ...... rotein zero-truncating mutants

@en

P2093

G Jackson Snipes

http://www.w3.org/2001/XMLSchema#string

James R Lupski

http://www.w3.org/2001/XMLSchema#string

Ken Inoue

http://www.w3.org/2001/XMLSchema#string

Mehrdad Khajavi

http://www.w3.org/2001/XMLSchema#string

Wojciech Wiszniewski

http://www.w3.org/2001/XMLSchema#string

P2860

Localization and functional analyses of the MLC1 protein involved in megalencephalic leukoencephalopathy with subcortical cysts

De novo mutation of the myelin P0 gene in Dejerine-Sottas disease (hereditary motor and sensory neuropathy type III)

Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations

Identification of a de novo insertional mutation in P0 in a patient with a Déjérine-Sottas syndrome (DSS) phenotype

Association of calnexin with mutant peripheral myelin protein-22 ex vivo: a basis for "gain-of-function" ER diseases

Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo

Nonsense-mediated mRNA decay in health and disease

When the message goes awry: disease-producing mutations that influence mRNA content and performance.

Flow cytometric assay for evaluation of the effects of cell density on cytotoxicity and induction of apoptosis.

Role and regulation of the ER chaperone BiP.

P304

841-850

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/497541

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7515009

http://www.w3.org/2001/XMLSchema#string

P698

16252242

http://www.w3.org/2001/XMLSchema#string

P921

endoplasmic reticulum

P932

1271391

http://www.w3.org/2001/XMLSchema#string